Clinical Trials
23 trialsNCT07619365 2026-06-02
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06271837 2026-05-11
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
Phase 2 Active not recruiting
NCT06048718 2026-05-08
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT06172127 2026-04-29
DEMETHER
MedSIR
Phase 2 Active not recruiting
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT07371585 2026-03-27
TOP-REAL
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT04539938 2026-03-23
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT07416253 2026-02-18
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04986579 2025-11-19
Scalp Cooling in MBC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04553770 2025-11-10
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06533826 2025-10-24
TRADE DXd
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05795101 2025-09-19
TRUDI
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07151586 2025-09-03
ALTER
UNICANCER
Phase 2 Not yet recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT03248492 2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2 Terminated
NCT06439693 2025-06-26
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04420598 2025-06-24
DEBBRAH
MedSIR
Phase 2 Completed
NCT04132960 2025-06-12
DAISY
UNICANCER
Phase 2 Completed
NCT06797622 2025-01-28
Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT04752059 2023-05-12
TUXEDO-1
Medical University of Vienna
Phase 2 Completed